# KEYNOTE-091 (NCT02504372)

> Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: completely resected stage IB-IIIA non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02504372
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pembrolizumab; Placebo
- Enrollment: 1177
- Primary outcome: Disease-Free Survival (DFS)
- Primary outcome: DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50%

## Indexed commentary on KEYNOTE-091 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 46
- X threads: 40
- Podcasts: 38
- Bluesky threads: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-091-nct02504372

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02504372", "email": "<work email>"}; the inbox owner confirms by the emailed link.